{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:54:38Z","timestamp":1760889278658},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00063-016-0185-5","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T05:30:26Z","timestamp":1477287026000},"page":"11-23","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmakokinetik und Pharmakodynamik von Antibiotika in der Intensivmedizin","Pharmacokinetics and pharmacodynamics of antibiotics in intensive care"],"prefix":"10.1007","volume":"112","author":[{"given":"F.","family":"S\u00f6rgel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"H\u00f6hl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Munz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vormittag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bulitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Junger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Holzgrabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"185_CR1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/clpt.1993.162","volume":"54","author":"S Allard","year":"1993","unstructured":"Allard S, Kinzig M, Boivin G et\u00a0al (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368\u2013373","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 1","key":"185_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","volume":"48","author":"JM Andrews","year":"2001","unstructured":"Andrews JM (2001) Determination of minimum inhibitory concentrations. J\u00a0Antimicrob Chemother 48(suppl 1):5\u201316","journal-title":"J Antimicrob Chemother"},{"key":"185_CR3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/AAC.40.1.139","volume":"40","author":"P Bourget","year":"1996","unstructured":"Bourget P, Lesne-Hulin A, Reveille R le et al (1996) Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40:139\u2013145","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01477-06","volume":"51","author":"JB Bulitta","year":"2007","unstructured":"Bulitta JB, Duffull SB, Kinzig-Schippers M et al (2007) Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 51:2497\u20132507","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-2125.2010.03750.x","volume":"70","author":"JB Bulitta","year":"2010","unstructured":"Bulitta JB, Kinzig M, Jakob V et\u00a0al (2010) Nonlinear pharmacokinetics of piperacillin in healthy volunteers\u2013implications for optimal dosage regimens. Br J Clin Pharmacol 70:682\u2013693","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/AAC.00936-09","volume":"54","author":"JB Bulitta","year":"2010","unstructured":"Bulitta JB, Landersdorfer CB, H\u00fcttner SJ et\u00a0al (2010) Population pharmacokinetic comparison and pharmacodynamics breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 54:1275\u20131282","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2015.06.016","volume":"46","author":"M Carlier","year":"2015","unstructured":"Carlier M, Stove V, Wallis SC et al (2015) Assays for therapeutic drug monitoring of \u03b2\u2011lactam antibiotics: a structured review. Int J Antimicrob Agents 46:367\u2013375","journal-title":"Int J Antimicrob Agents"},{"key":"185_CR8","first-page":"507","volume":"1","author":"WK Cheung","year":"1989","unstructured":"Cheung WK, Greene DS, Kuye O et\u00a0al (1989) Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration. J\u00a0Chemother 1:507\u2013508","journal-title":"J Chemother"},{"key":"185_CR9","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/AAC.36.12.2577","volume":"36","author":"WA Craig","year":"1992","unstructured":"Craig WA, Ebert SC (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36:2577\u20132583","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","volume":"17","author":"WA Craig","year":"2003","unstructured":"Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479\u2013501","journal-title":"Infect Dis Clin North Am"},{"key":"185_CR11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/cid\/ciu055","volume":"58","author":"WA Craig","year":"2014","unstructured":"Craig WA (2014) Are blood concentrations enough for establishing pharmacokinetic\/pharmacodynamic relationships? Clin Infect Dis 58:1084\u20131085","journal-title":"Clin Infect Dis"},{"key":"185_CR12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1044-0305(03)00574-9","volume":"14","author":"R Dams","year":"2003","unstructured":"Dams R, Huestis MA, Lambert WE et al (2003) Matrix effect in bio-analysis of illicit drugs with LC-MS\/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom 14:1290\u20131294","journal-title":"J Am Soc Mass Spectrom"},{"issue":"Suppl B","key":"185_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/9.suppl_B.49","volume":"9","author":"PJ Schepper de","year":"1982","unstructured":"Schepper PJ de, Tjandramaga TB, Mullie A et\u00a0al (1982) Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J\u00a0Antimicrob Chemother 9(Suppl B):49\u201357","journal-title":"J Antimicrob Chemother"},{"key":"185_CR14","volume-title":"Der Blutspiegel \u2013 Kinetik der Konzentrationsabl\u00e4ufe in der Kreislauffl\u00fcssigkeit","author":"FH Dost","year":"1953","unstructured":"Dost FH (1953) Der Blutspiegel \u2013 Kinetik der Konzentrationsabl\u00e4ufe in der Kreislauffl\u00fcssigkeit. Thieme, Leipzig"},{"key":"185_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/cid\/cis863","volume":"56","author":"GL Drusano","year":"2013","unstructured":"Drusano GL, Lodise TP (2013) Saving lives with optimal antimicrobial chemotherapy. Clin Infect Dis 56:245\u2013247","journal-title":"Clin Infect Dis"},{"key":"185_CR16","unstructured":"Ehrlich P, pers\u00f6nliche Notiz (von Paul Ehrlich \u201eBlock\u201c genannt) im Rockefeller Archive Center (RAC) in Sleepy Hollow"},{"key":"185_CR17","first-page":"710","volume":"2","author":"P Ehrlich","year":"1881","unstructured":"Ehrlich P (1881) Ueber das Methylenblau und seine klinisch-bakterioskopische Verwerthung. Z Klin Med 2:710\u2013713","journal-title":"Z Klin Med"},{"key":"185_CR18","first-page":"364","volume-title":"Paul Ehrlich gesammelte Werke Band I","author":"P Ehrlich","year":"1956","unstructured":"Ehrlich P (1956) Das Sauerstoff-Bed\u00fcrfnis des Organismus. Eine farbenanalytische Studie. In: Paul Ehrlich gesammelte Werke Band I. Springer, Berlin Heidelberg, S 364\u2013432 (urspr\u00fcnglich erschienen bei Hirschwald, Berlin 1885)"},{"key":"185_CR19","first-page":"953","volume":"28","author":"P Ehrlich","year":"1891","unstructured":"Ehrlich P, Guttmann P (1891) Ueber die Wirkung des Methylenblau bei Malaria. Berl Klin Wochenschr 28:953\u2013995","journal-title":"Berl Klin Wochenschr"},{"key":"185_CR20","first-page":"2481","volume":"58","author":"P Ehrlich","year":"1911","unstructured":"Ehrlich P (1911) Ueber Salvarsan. Munch Med Wochenschr 58:2481\u20132486","journal-title":"Munch Med Wochenschr"},{"key":"185_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5603\/AIT.a2015.0080","volume":"47","author":"PW Elbers","year":"2015","unstructured":"Elbers PW, Girbes A, Malbrain ML et\u00a0al (2015) Right dose, right now: using big data to optimize antibiotic dosing in the critically ill. Anaesthesiol Intensive Ther 47:457\u2013463","journal-title":"Anaesthesiol Intensive Ther"},{"key":"185_CR22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.talanta.2013.03.048","volume":"115","author":"A Furey","year":"2013","unstructured":"Furey A, Moriarty M, Bane V et\u00a0al (2013) Ion suppression; a critical review on causes, evaluation, prevention and applications. Talanta 115:104\u2013122","journal-title":"Talanta"},{"key":"185_CR23","first-page":"1","volume":"1","author":"EE Goldman","year":"1913","unstructured":"Goldman EE (1913) Vitalf\u00e4rbung am Zentralnervensystem. Abhandlungen der K\u00f6niglich Preussischen Akademie der Wissenschaften \/ Physikalisch-Mathematische Klasse 1:1\u201313","journal-title":"Abhandlungen der K\u00f6niglich Preussischen Akademie der Wissenschaften \/ Physikalisch-Mathematische Klasse"},{"key":"185_CR24","volume-title":"Goodman\u2018 & Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2011","unstructured":"Brunton LL, Chabner BA, Knollman BC (2011) Goodman\u2018 & Gilman\u2019s the pharmacological basis of therapeutics, 12.\u00a0Aufl. Mac Graw Hill Medical, New York","edition":"12"},{"key":"185_CR25","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1128\/AAC.36.9.1997","volume":"36","author":"M Kinzig","year":"1992","unstructured":"Kinzig M, S\u00f6rgel F, Brismar B et\u00a0al (1992) Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother 36:1997\u20132004","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","volume":"49","author":"WA Krueger","year":"2005","unstructured":"Krueger WA, Bulitta J, Kinzig-Schippers M et al (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881\u20131889","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2125.2008.03266.x","volume":"66","author":"CB Landersdorfer","year":"2008","unstructured":"Landersdorfer CB, Kirkpatrick CM, Kinzig M et\u00a0al (2008) Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol 66:648\u2013659","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M et\u00a0al (2009) Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalyticalconsiderations. Clin Pharmacokinet 48:89\u2013124","journal-title":"Clin Pharmacokinet"},{"key":"185_CR29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2125.2009.03564.x","volume":"69","author":"CB Landersdorfer","year":"2010","unstructured":"Landersdorfer CB, Kirkpatrick CM, Kinzig M et\u00a0al (2010) Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol 69:167\u2013178","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR30","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1128\/AAC.00937-12","volume":"56","author":"CB Landersdorfer","year":"2012","unstructured":"Landersdorfer CB, Bulitta JB, Kirkpatrick CM et\u00a0al (2012) Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother 56:5715\u20135723","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","volume":"68","author":"LS Lee","year":"2010","unstructured":"Lee LS, Kinzig-Schippers M, Nafziger AN et al (2010) Comparison of 30-min and 3\u2011h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 68:251\u2013258","journal-title":"Diagn Microbiol Infect Dis"},{"key":"185_CR32","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00216-013-7542-5","volume":"406","author":"KS Leung","year":"2014","unstructured":"Leung KS, Fong BM (2014) LC-MS\/MS in the routine clinical laboratory: has its time come? Anal Bioanal Chem 406:2289\u20132301","journal-title":"Anal Bioanal Chem"},{"key":"185_CR33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jac\/dkm325","volume":"60","author":"TP Lodise","year":"2007","unstructured":"Lodise TP, Nau R, Kinzig M et\u00a0al (2007) Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J\u00a0Antimicrob Chemother 60:1038\u20131044","journal-title":"J Antimicrob Chemother"},{"key":"185_CR34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E et al (2014) Vancomycin exposure in patients with methicillin-resistant staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 59:666\u2013675","journal-title":"Clin Infect Dis"},{"key":"185_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","volume":"14","author":"JW Mouton","year":"2011","unstructured":"Mouton JW, Ambrose PG, Canton R et\u00a0al (2011) Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 14:107\u2013117","journal-title":"Drug Resist Updat"},{"key":"185_CR36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cmi.2015.06.007","volume":"21","author":"AE Muller","year":"2015","unstructured":"Muller AE, Theuretzbacher U, Mouton JW (2015) Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective. Clin Microbiol Infect 21:881\u2013885","journal-title":"Clin Microbiol Infect"},{"key":"185_CR37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H (2010) Penetration of drugs through theblood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23:858\u2013883","journal-title":"Clin Microbiol Rev"},{"key":"185_CR38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jac\/dku437","volume":"70","author":"VE Rees","year":"2015","unstructured":"Rees VE, Bulitta JB, Nation RL et al (2015) Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in pseudomonas aeruginosa. J Antimicrob Chemother 70:818\u2013826","journal-title":"J Antimicrob Chemother"},{"key":"185_CR39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498\u2013509","journal-title":"Lancet Infect Dis"},{"key":"185_CR40","doi-asserted-by":"crossref","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS et al (2016) Continuous versus intermittent beta-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. doi:10.1164\/rccm.201601-0024OC","DOI":"10.1164\/rccm.201601-0024OC"},{"key":"185_CR41","first-page":"657","volume":"105","author":"A Rodloff","year":"2008","unstructured":"Rodloff A, Bauer T, Ewig S et\u00a0al (2008) Sensibel, intermedi\u00e4r und resistent \u2013 Wirkintensit\u00e4t von Antibiotika. Dtsch Arztebl 105:657\u2013662","journal-title":"Dtsch Arztebl"},{"key":"185_CR42","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","volume":"51","author":"SG Sakka","year":"2007","unstructured":"Sakka SG, Glauner AK, Bulitta JB et al (2007) Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51:3304\u20133310","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijantimicag.2013.10.008","volume":"43","author":"A Smits","year":"2014","unstructured":"Smits A, Roberts JA, Vella-Brincat JW et al (2014) Cefazolin plasma protein binding in different human populations: more than cefazolin-albumin interaction. Int J Antimicrob Agents 43:199\u2013200","journal-title":"Int J Antimicrob Agents"},{"key":"185_CR44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01647751","volume":"15","author":"F S\u00f6rgel","year":"1987","unstructured":"S\u00f6rgel F, Stephan U, Wiesemann HG et al (1987) High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection 15:385\u2013396","journal-title":"Infection"},{"key":"185_CR45","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/BF01745246","volume":"20","author":"F S\u00f6rgel","year":"1994","unstructured":"S\u00f6rgel F, Kinzig M (1994) Pharmacokinetic characteristics of piperacillin\/tazobactam. Intensive Care Med 20:S14\u2013S20","journal-title":"Intensive Care Med"},{"key":"185_CR46","first-page":"65","volume":"3","author":"F S\u00f6rgel","year":"2003","unstructured":"S\u00f6rgel F (2003) Warum Ikarus abst\u00fcrzte und PK\/PD doch ganz sch\u00f6n sexy ist: \u00dcberlegungen zur \u201emodernen\u201c Antibiotika-Therapie. Chemother J 3:65\u201370","journal-title":"Chemother J"},{"key":"185_CR47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pauz.200600191","volume":"35","author":"F S\u00f6rgel","year":"2006","unstructured":"S\u00f6rgel F, Bulitta J, Landersdorfer C (2006) What we know and what we want to know about beta-lactams. Pharmacokinetics and pharmacodynamics of beta lactams. Pharm Unserer Zeit 35:438\u2013451","journal-title":"Pharm Unserer Zeit"},{"key":"185_CR48","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1128\/AAC.00849-15","volume":"59","author":"U Theuretzbacher","year":"2015","unstructured":"Theuretzbacher U, Ambrose PG, MacGowan AP et\u00a0al (2015) In memoriam: William A. Craig. Antimicrob Agents Chemother 59:2971","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1128\/AAC.14.6.829","volume":"14","author":"TB Tjandramaga","year":"1978","unstructured":"Tjandramaga TB, Mullie A, Verbesselt R et\u00a0al (1978) Piperacillin: human pharmacokinetics after intravenous and Intramuscular administration. Antimicrob Agents Chemother 14:829\u2013837","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mas.20298","volume":"30","author":"H Trufelli","year":"2011","unstructured":"Trufelli H, Palma P, Famiglini G et al (2011) An overview of matrix effects in liquid chromatography-mass spectrometry. Mass Spectrom Rev 30:491\u2013509","journal-title":"Mass Spectrom Rev"},{"key":"185_CR51","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jchromb.2009.01.003","volume":"877","author":"A Eeckhaut Van","year":"2009","unstructured":"Van Eeckhaut A, Lanckmans K, Sarre S et al (2009) Validation of bioanalytical LC-MS\/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 877:2198\u20132207","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"185_CR52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1128\/AAC.23.6.881","volume":"23","author":"PG Welling","year":"1983","unstructured":"Welling PG, Craig WA, Bundtzen RW (1983) Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother 23:881\u2013887","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.35.6.1081","volume":"35","author":"R Wise","year":"1991","unstructured":"Wise R, Logan M, Cooper M et\u00a0al (1991) Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 35:1081\u20131084","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR54","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","volume":"57","author":"G Wong","year":"2013","unstructured":"Wong G, Briscoe S, Adnan S et al (2013) Protein binding of \u03b2\u2011lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165\u20136170","journal-title":"Antimicrob Agents Chemother"},{"key":"185_CR55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-14-288","volume":"14","author":"G Wong","year":"2014","unstructured":"Wong G, Sime FB, Lipman J et\u00a0al (2014) How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis 14:288","journal-title":"BMC Infect Dis"},{"key":"185_CR56","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0091270009337133","volume":"49","author":"SL Wong","year":"2009","unstructured":"Wong SL, S\u00f6rgel F, Kinzig M et\u00a0al (2009) Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin\/tazobactam in healthy participants. J\u00a0Clin Pharmacol 49:816\u2013823","journal-title":"J Clin Pharmacol"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-016-0185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-016-0185-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-016-0185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:08:15Z","timestamp":1718856495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-016-0185-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1007\/s00063-016-0185-5","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}